Immunisation Advisory Centre |

Vertical Tabs

Introduction

Dear Colleagues

Welcome to the 2017 New Zealand Immunisation Conference. This year marks our 10^th Conference - a great milestone indeed!

This conference is an excellent opportunity to consider the recent changes and upcoming challenges in the immunisation landscape. On a local New Zealand level, 2017 is a year of change and whilst we will still be bedding in the new Immunisation Schedule, there are bound to be some salient lessons already to ponder.

We are very honoured to introduce Dr Steven Black as one of our international keynote speakers. Dr Black is a pediatric infectious disease specialist who has spent more than 30 years conducting clinical trials and safety studies of vaccines. He has been principal investigator in five pivotal licensure trials and six phase-four post-marketing trials. Dr Black is currently Professor of Pediatrics in the Center for Global Health at the University of Cincinnati Children’s Hospital in Ohio USA. He received his MD degree from the University of California, San Diego and specialty training in pediatric infectious diseases at the University of California, San Francisco. His academic interests include the epidemiology of vaccine preventable diseases, the use of clinical databases to evaluate vaccine safety and efficacy, conducting vaccine clinical trials as well as vaccine safety assessment in the developing world.

Dr Peter Hotez, President of the Sabin Vaccine Institute will join us remotely. Dr Hotez is a Professor of Pediatrics and Molecular Virology & Microbiology at Baylor College of Medicine. He also serves as Director of the Texas Children’s Hospital Center for Vaccine Development and the Baker Institute Fellow in Disease and Poverty at Rice University. His research focuses on developing vaccines for neglected tropical diseases that affect hundreds of millions of children and adults worldwide.

Along with our Australasian and Oceanic colleagues, I’m sure this year’s programme will provide you all with valuable opportunities to consider new perspectives, refresh friendships and boost the batteries as we push towards a country and world where the impact of preventable disease fades.

I look forward to seeing you all in September

Best wishes

Dr Nikki Turner

Director, the Immunisation Advisory Centre.

Programme outline

Please click on the image below to view the final programme of the pre-conference Workshop and Conference (posted 24th August 2017)

Workshop and Conference programme

Accommodation

We've collated some popular accommodation options. Contact details are provided so delegates can get in touch with their preferred accommodation option directly.

All of these are within a 10 minute walk to the conference venue. Please note that the conference organiser is not responsible for delegates’ accommodation.

Ibis 153 Featherston Street Wellington	website
Novotel 133 The Terrace Wellington	website
Rydges 75 Featherston St Wellington	website
James Cook Hotel Grand Chancellor 147 The Terrace Wellington	website
Park Hotel Lambton Quay 101 The Terrace Wellington	website
The Thorndon 24 Hawkestone St, Thorndon Wellington	website
Intercontinental 2 Grey St Wellington	website

Speakers

Professor Steve Black

Professor of Pediatrics in the Center for Global Health at the University of Cincinnati Children’s Hospital in Ohio, USA

Specialising in paediatric infectious diseases, his academic interests include the epidemiology of vaccine preventable diseases, the use of clinical databases to evaluate vaccine safety and efficacy and the conduct of vaccine clinical trials as well as vaccine safety assessment in the developing world. He will discuss vaccine safety and safety systems. He will also provide evidence for effectiveness and safety of live attenuated varicella and zoster vaccines.

Charles Blanch

Director of Emergency Management, Protection Regulation and Assurance - Emergency Management Team, Ministry of Health

Charlie is a certified emergency manager with 18 years of experience across Regional and National government in Reduction, Readiness, Response and Recovery activity for a wide range of hazards.His teams lead readiness planning for pandemic influenza including maintenance of the National Reserve Supplies and engagement with other agencies and sectors to ensure their readiness. His national leadership roles include work in the National Health Coordination Centre Response Manager during the 2009 H1N1 pandemic, the Health National Coordinator for the Canterbury Earthquakes, as well as health sector representation to a wide range of national security system events from the Rugby World Cup to the Hawkes Bay gastro outbreak. In 2015 he deployed with the World Health Organization as the emergency medical team coordinator in Sierra Leone for 3 months and has also led assessment missions with the New Zealand Medical Assistance Team.

Professor Anne La Flamme

Professor, School of Biological Sciences, Victoria University,Wellington

Professor Anne Camille La Flamme leads the Multiple Sclerosis Research Programme at the Malaghan Institute of Medical Research. After receiving her doctorate in Immunoparasitology from the University of Washington, Seattle, Prof La Flamme spent several years at Cornell University studying how schistosome worms alter the host's immune response and cause immune-mediated pathology. From this work, she developed a research programme in Th2 response regulation by macrophages and their involvement in immune-mediated diseases such as multiple sclerosis. Her current focus is on translational research in multiple sclerosis.

Professor Peter Hotez

Professor of Pediatrics and Molecular Virology & Microbiology at Baylor College of Medicine

Founding dean of the National School of Tropical Medicine in the USA, President of the Sabin Vaccine Institute and a professor of Pediatrics and Molecular Virology & Microbiology at Baylor College of Medicine, Dr. Hotez’s research focuses on developing vaccines for neglected tropical diseases that affect hundreds of millions of children and adults worldwide. He will discuss the global burden of disease and international challenges in improving equity and global advocacy of immunisation. He will also provide insight into the future of emerging vaccines and scheduling.

Susan Kenyon

Principal Technical Specialist – Pharmacovigilance, Clinical Risk Management, Medsafe, Ministry of Health

Susan graduated from the University of London, School of Pharmacy as a pharmacist and with a PhD in biochemistry. Susan later joined the Medicines and Healthcare products Regulatory Agency (MHRA) as a pharmacovigilance assessor, where she was responsible for monitoring the safety of anti-retroviral medicines throughout the UK and Europe. Since joining Medsafe as a senior pharmacovigilance advisor in 2008, Susan has been responsible for activities such as the cough and cold review group, the M² scheme, the suspected medicines adverse reactions search (SMARS), the early warning communication system, updating the Medsafe website and the New Zealand pharmacovigilance guidelines, and changing the format of data sheets.

Professor Helen Marshall

Professor of Vaccinology, Adelaide Medical School, University of Adelaide.

Also senior Medical Practitioner and Medical Director, Vaccinology and Immunology Research Trials Unit, VIRTU, Women’s and Children’s Hospital, Professor Marshall is a medical researcher and NHMRC Senior Fellow with specialist training in child health, public health and vaccinology at the University of Adelaide. Her research programme is directed to prevention of serious infections in children and includes clinical trials in investigational vaccines, infectious and social epidemiology and public health. Her main interests include meningococcal, human papillomavirus, influenza and pertussis infections and their prevention by immunisation. She is the Principal Investigator of the South Australian Meningococcal B vaccine carriage study “B Part of It” to assess the impact of 4CMenB vaccine on oropharyngeal carriage in adolescents. In recognition of her research leadership she was awarded the South Australia Science Award for Excellence in Research for the Public Good.

Caroline McElnay

Director of Public Health, Protection Regulation and Assurance, Public Health, Ministry of Health

Dr Caroline McElnay is the Director of Public Health, at the Ministry of Health, New Zealand. She has been in this role since March 2017, having previously worked in Hawke's Bay as a public health physician, medical officer of health and member of the HBDHB executive team. She has a long standing interest and experience in immunisation and is a member of the PHARMAC immunisation subcommittee. In her role as DPH she works closely with the MoH Immunisation team providing support and clinical advice.

Professor Peter McIntyre

Director of National Centre of Immunisation Research and Surveillance for Vaccine Preventable Disease (NCIRS),

A Professor of Child and Adolescent Health at Children’s Hospital Westmead, University of Sydney, Peter’s major specific research interests are in bacterial VPDs, including Haemophilus influenzae type b, pneumococcus and pertussis, including measurement of vaccine effectiveness and risk factors using case-control studies and linked data sets and post implementation evaluation of vaccine programs.

Associate Profession Michael Nissen

Director of Scientific Affairs & Public Health for GSK Vaccines in the Asia Pacific region.

Prior to his current role, Michael Nissen was the director of Infectious Diseases at the Royal Children’s Hospital and a practising Clinical Microbiologist at the Royal Brisbane & Women’s Hospitals in Brisbane from 2000 to 2014. As a member of the Australian Technical Advisory Group for Immunisation from 2007 to 2013, was overseeing two editions of the Australian Immunisation Handbook and chaired the Haemophilus influenzae, Meningococcal C, Meningococcal and Rabies Working Parties. Other immunisation duties included Chair of the Australian National Verification Committee for the Elimination of Measles (2013-2014) and membership of the Australian Influenza Vaccination Committee (2013-2014). Michael trained in Paediatrics, Infectious Diseases and Clinical Microbiology in Australia and the USA. His research interests include the epidemiology and prevention of bacterial infections by vaccination and the rapid molecular diagnostic techniques of infectious diseases.

Dr Michael Tatley

Director of New Zealand Pharmacovigilance Centre, University of Otago, Medical Assessor for CARM and Acting Director of the National Poisons Centre, Dunedin

Dr Michael Tatley is a public health physician and is the Director of the New Zealand Pharmacovigilance Centre at the University of Otago, comprising of the Centre for Adverse Reactions Monitoring (CARM) and the Medication Error Reporting Program (MERP). He continues to be involved in the ongoing evaluation of adverse event reports to CARM and high level of support in reports to CARM of adverse events following immunisation in New Zealand. Prior to his move to New Zealand, he was a Medical Officer of Health in Metropolitan Cape Town, South Africa. These experiences have led to an increasing interest in the “vaccine–vigilance” aspects of the NZ National Centre activities. He has been a member of the Medicines Adverse Reactions Committee since 2000 and is a consultant reviewer for the World Health Organization’s Programme for International Drug monitoring.

Litiana Volavola

National EPI Coordinator, Fiji Pharmaceutical Services and Biomedical Centre, Fiji.

Litiana is a public health nurse, the Vaccine Procurement and Supplies officer for Fiji and the co-ordinator for the Monitoring of AEFIs through Pharmacovigilance under the Fiji Medicine Inspectorate Regulatory Authority. She is directly involved in the Monitoring and Evaluation of the Fiji EPI Programme. Litiana is a member of the Vaccine Preventable Disease (VPD) Committee, National Influenza Taskforce Committee and of the Pacific Immunisation Strengthening Programme in the Pacific (PIPS). Litiana will be presenting on the challenges Fiji and the other Pacific Island countries face in their Expanded Program on Immunization (EPI) Programs.

Supporters

Major Conference Supporter

GSK is a research-based pharmaceutical and healthcare company operating in more than 100 countries around the world. Our mission is to improve the quality of human life by enabling people to do more, feel better and live longer. At this year’s Conference, we welcome you to come and visit our place and see how we bring those values to life. We promise you a warm welcome where you’ll feel right at home. That’s as it should be given GSK has been part of the New Zealand health landscape since the 1880s. You’ll learn about the important role we have of protecting New Zealanders throughout life with our broad portfolio of vaccines.

Major Conference Supporter

Sanofi Pasteur

Sanofi is a global life sciences company committed to improving access to healthcare and supporting the people we serve throughout the continuum of care. From prevention to treatment, Sanofi transforms scientific innovation into healthcare solutions, in human vaccines, rare diseases, multiple sclerosis, oncology, immunology, infectious diseases, diabetes and cardiovascular solutions, and consumer healthcare.

Sanofi's 110,000 people, some 820 of them in Australia and New Zealand, are dedicated to making a difference to patients’ daily lives. Sanofi Pasteur, the vaccines division of Sanofi, provides more than 1 billion doses of vaccine each year, making it possible to immunize more than 500 million people across the globe.

A world leader in the vaccine industry, Sanofi Pasteur produces a portfolio of high quality vaccines that matches its areas of expertise and meets public-health demand. The company's heritage, to create vaccines that protect life, dates back more than a century. Sanofi Pasteur is the largest company entirely dedicated to vaccines. Every day, the company invests more than EUR 1 million in research and development.

Conference Supporter

Seqirus, formerly bioCSL markets vaccines and pharmaceutical products in New Zealand with a focus on products for the prevention and treatment of many serious human medical conditions. Seqirus is recognised as a leading supplier of vaccines and specialty pharmaceuticals to New Zealand. We are an innovative organisation with a strong emphasis on relationships.

Entertainment and Refereshment Sponsor

Green Cross Health Limited is a leading primary healthcare provider, delivering healthcare solutions to communities the length and breadth of New Zealand.

We represent more than 350 community pharmacies throughout New Zealand under the Unichem and Life Pharmacy brands. Our Medical Division provides complete family healthcare services through GP, accident and medical centres, with many operating under The Doctors brand. Green Cross Health provides home health care and community nursing to more than 21,000 people, serviced primarily by the team at Access Community Health. This team is dedicated to giving clients the care and support they need to live independently in their communities throughout New Zealand.

Victoria University is proud to be supporting the 10^th New Zealand Immunisation Conference.

Improving Health and Wellbeing in our communities is important to Victoria, and has been identified as one of eight areas of academic distinctiveness—these are areas where Victoria has both research and teaching strength, and where we can most effectively contribute to local, national and global challenges.

We are home to two leading biomedical research centres, the Centre for Biodiscovery and the Ferrier Research Institute and work closely with the Malaghan Institute of Medical Research on understanding and developing novel treatments for disease.

Thanks to our proximity to the central government, District Health Boards, and many NGOs, we are also making major contributions to understanding how health outcomes can be improved by better policy settings, increased education, new technology, and reduced inequality.

Location

Rutherford House is located at the corners of Bunny St. and Lambton Quay

Contact

For all Conference enquiries please email the Conference Convenor:

Theo Brandt, t.brandt@auckland.ac.nz

Submit an abstract

The 10^th New Zealand Immunisation Conference Academic Committee invites the submission of abstracts of original work.
Abstracts can be submitted for an oral presentation or a hard copy poster, in the following themes:

Immunisation programmes and policy
Immunisation coverage and service delivery
Vaccine preventable diseases and vaccine effectiveness
Vaccine safety
Media and communication
Other

All abstracts must include the following information. We suggest preparing your abstract and then cutting and pasting into the online application form.

Title
Author’s names and institutions
Introduction
Methods
Results and discussion
Conclusions
Conflicts of interest
References

Please adhere to a total word count not exceeding 350 words, not including title, author’s name(s) and references. No figures or images can be submitted.
Poster abstracts are submitted using the same form as the oral presentation abstracts. Click here for a brief poster guide.
Please limit references to a maximum of three.

Abstract submissions EXTENDED to close Sunday 16th of July at 8:00 pm NZT

Abstracts submission has now closed, please contact us if needed.

Registration

Registrations have now closed. For any enquiries contact Theo Brandt on t.brandt@auckland.ac.nz

Vertical Tabs

Dear Colleagues

Major Conference Supporter

Major Conference Supporter

Sanofi Pasteur

Conference Supporter

Entertainment and Refereshment Sponsor

Victoria University is proud to be supporting the 10th New Zealand Immunisation Conference.

Abstracts submission has now closed, please contact us if needed.

Victoria University is proud to be supporting the 10^th New Zealand Immunisation Conference.